News

An analysis of more than a dozen cohort studies containing data from more than 30,000 offspring provides clinicians with the most detailed overview yet of differences in cardiometabolic health outcomes in those conceived naturally compared to those conceived with use of assisted reproductive technologies.

New research into egg, peanut allergies and sensitization raised questions about allergy incidence rates and early exposure.

An analysis of data from the Rochester Epidemiology Project suggests those with breast cancer or lymphoma who received treatment with anthracycline therapy experienced a more than doubling in risk of heart failure compared to controls without cancer.

Amid a blood shortage and continued stigmatization of HIV risk, it's hard to feel good about the FDA's delayed decision—though good may still come of it.

The majority of included studies observed improvements in pain, fatigue, patient global, sleep disturbance, multidimensional function, and tender points.

The Sickle Cell Trait Awareness Campaign (STAC) offers promising possibilities of expanding sickle cell trait education across the country, Dr. Carolyn Rowley and Pat Corley, RN explain.

Our latest endocrine case report from Brady Pregerson, MD, features a patient in their mid-60’s presenting to the hospital with approximately 2 days of gradually worsening right elbow pain. Can you determine the correct diagnosis?

An international review of data show certain antidepressants may benefit conditions like fibromyalgia, but many trials are actually inconclusive.

While 20% of the patient population had a Fib-4 index greater than 1.3, including 1 case of a Fib-4 index greater than 2.67, the investigators did not identify a significant increase in Fib-4 index in patients with fatty liver compared to those who did not develop fatty liver.

The January 2023 ophthalmology month in review features modifications in age-related macular degeneration risk, links between ophthalmic disease and quality of life, and complications during cataract surgery.

A list of the top stories covered this week in the dermatology field, with data on breakthroughs, new research, and advanced treatment options.

The sBLA for lanadelumab permits its use as a prophylaxis in children as young as 2 years old with the rare condition.

Individuals with sickle cell trait not only need to know their status to make informed family planning decisions, but also so they can watch out for the possible symptoms.

In recognition of Go Red for Women Day on February 3, this feature shines a spotlight on the hurdles faced by women in cardiology and offers perspective on the battle for gender-based equity in medicine from the perspective of a pair of female leaders.

Anakinra effectively treated 94% of the gout flares included in the study sample and was a viable long-term treatment option.

The mRNA vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) showed no risk of Guillain-Barré syndrome post-vaccination.

In a Dutch population, greater sedentary behavior was associated with an increased risk of DED, but data suggest the association was only significant for those with less than recommended physical activity.

Adult patients with psoriatic arthritis starting a second-line biological after discontinuing a TNF were enrolled in the nationwide cohort study.

Real-world data suggest nAMD eyes can extend injection intervals by switching to brolucizumab from other anti-VEGF therapies, while maintaining vision and reducing CMT.

In recent research into alopecia areata treatments, selective JAK1 inhibition was tested as a means for restoring hair growth.

Older age and use of various medications, including antibiotics, proton pump inhibitors, and corticosteroids were associated with a higher risk of developing C difficile infections.

An analysis of data from the China Kadoorie Biobank study suggests cumulative exposure to estrogen was associated with stroke risk in postmenopausal women.

The rate of adverse events was lower in the combination group than it was in patients in the guselkumab or golimumab monotherapy groups at week 50.

New research demonstrated that 5-fluorouracil and microneedling in conjunction showed stronger results for the 19 participants than tacrolimus monotherapy as a treatment for vitiligo.

“Reversing and preventing adverse lifestyle factors could potentially reduce the incidence and burden of rheumatoid arthritis, as well as alleviate its comorbidities,” investigators hypothesized.

Dr. Carolyn Rowley explains, the whole reason for the Sickle Cell Trait Awareness Campaign (STAC) is to start talking about it.

Two-year data suggest the average cost of aflibercept monotherapy was approximately $26, 500 compared with approximately $14, 000 for the bevacizumab-first group in eyes with center-involved DME.

Investigators measured pain intensity, the primary outcome, as well as physical function, isometric strength, quality of life, and fibromyalgia impact at baseline and the 6-month mark.

On February 2, Abbott announced their FlexAbility™ Ablation Catheter, Sensor Enabled had received an expanded approval from the US Food and Drug Administration and their TactiFlex™ Ablation Catheter, Sensor Enabled received a CE Mark.

"Despite advances in SCD management and high-risk pregnancy care, at the national level, outcomes in this population have not improved since the last NIS analysis of data from 1999 to 2008," investigators write.